E

Evolus
D

EOLS

13.990
USD
-0.63
(-4.31%)
مغلق
حجم التداول
23,789
الربح لكل سهم
0
العائد الربحي
-
P/E
-15
حجم السوق
885,867,687
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    BDX
    BDX
    -0.590
    (-0.26%)
    227.450 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    JNJ
    JNJ
    2.680
    (1.68%)
    162.370 USD
    LLY
    LLY
    0.67
    (0.08%)
    874.04 USD
    MDT
    MDT
    2.000
    (2.27%)
    89.940 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    NVS
    NVS
    2.100
    (1.96%)
    109.370 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    المزيد
الأخبار
المقالات

العنوان: Evolus

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.